CDX2 and neoplasm: Inferior OS was also observed for patients with CDX2-negative (N = 8) compared to CDX2-positive (N = 157) tumours when adjusted to exclude samples with the BRAF p.V600E variant (median 18 versus 103 months, respectively; Mantel-Cox log-rank test, p = 0.043; Figure 4B).